UCL spinout Echopoint Medical secures £4.2m Series A
Posted
Echopoint Medical, a cardiovascular diagnostic technology company and a UCL spinout, has secured £4.2 million in Series A funding, primarily to advance its iKOr system through FDA approval for the US market. The iKOr system, developed following a successful clinical trial at St Bartholomew’s Hospital, aims to improve coronary flow assessments, particularly benefiting women with angina.
The funding round, led by existing investors Parkwalk Advisors and us at UCL Technology Fund, with support from UCL Business, reflects confidence in Echopoint’s vision. With this funding, Echopoint aims to navigate FDA’s stringent approval process, and launch the iKOr system in the US to further solidifying Echopoint Medical’s position as a leader in the field, potentially revolutionizing interventional cardiology.
Antony Odell, CEO of Echopoint Medical Ltd, expressed his gratitude for the robust support from investors: “This investment is not just a financial milestone; it’s a vote of confidence in our vision to transform interventional cardiology diagnostics and patient care. Our roots as a UCL spinout, combined with the expertise and dedication of our team, place us in a unique position to bring the iKOr system to the forefront of medical technology.”
“It’s been great to partner with Echopoint right from their beginnings in the lab at UCL through to leading their Seed round and now supporting their Series A. We’ve been hugely impressed with the team’s ability to rapidly commercialise world leading university research and bring new fibre optic technology to deliver positive outcomes for end patients in the UK. We continue to support the company as they look to enter and scale across the US to help thousands suffering from microvascular disease.”
David Grimm, Partner AlbionVC